Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergovac Depot (ROXALL Medizin GmbH)
- Development stage
- Approved
- Lead developer
- Roxall Medicina España
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Allergovac Depot is a subcutaneous allergen immunotherapy (SCIT) product developed by Roxall Medicina España S.A. It consists of standardized allergen extracts, such as House Dust Mite (HDM) proteins, adsorbed onto an aluminum hydroxide adjuvant to facilitate a depot effect. This formulation allows for the gradual release of allergens at the injection site, which enhances the safety profile and promotes long-term immunological tolerance. The drug works by shifting the immune response from a Th2-dominated allergic profile to a Th1 and regulatory T-cell (Treg) response. This shift leads to the production of allergen-specific IgG4 "blocking" antibodies, which compete with IgE for allergen binding, thereby preventing mast cell and basophil degranulation. It is primarily investigated for the treatment of allergic rhinoconjunctivitis and allergic asthma triggered by specific environmental allergens.
- Brand names
- Allergovac Depot
- Other names
- Allergovac Depot HDMAllergovac Depot House Dust MiteAllergovac Depot Dermatophagoides
02
Targets
IgE (Immunoglobulin E)MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on Allergovac Depot (ROXALL Medizin GmbH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allergovac Depot (ROXALL Medizin GmbH).